ArticlePloS one2013
Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load?
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Clinical relevance of Pseudomonas aeruginosa viable but non-culturable forms in cystic fibrosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Involvement of Acquired Tobramycin Resistance in the Shift to the Viable but Non-Culturable State inInternational journal of molecular sciences · 2023Article
- Pseudomonas aeruginosa in tracheal aspirate: Colonization, infection, and recurrence.The clinical respiratory journal · 2023Article
- Optimization of Propidium Monoazide qPCR (Viability-qPCR) to Quantify the Killing by theAntibiotics (Basel, Switzerland) · 2022Article
- Pseudomonas aeruginosa in the Cystic Fibrosis Lung.Advances in experimental medicine and biology · 2022Article
- 2-Alkyl-4-quinolone quorum sensing molecules are biomarkers for culture-independentJournal of medical microbiology · 2021Article
- Contribution of Drugs Interfering with Protein and Cell Wall Synthesis to the Persistence ofInternational journal of molecular sciences · 2021Article
- Role of Tobramycin in the Induction and Maintenance of Viable but Non-CulturableAntibiotics (Basel, Switzerland) · 2020Article
- Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2).Scientific reports · 2019Article
- Detection of viable but non-culturable Pseudomonas aeruginosa in cystic fibrosis by qPCR: a validation study.BMC infectious diseases · 2018Article
- Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.Expert review of respiratory medicine · 2018Review
- Heparin-binding protein in sputum as a marker of pulmonary inflammation, lung function, and bacterial load in children with cystic fibrosis.BMC pulmonary medicine · 2018Article
- Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms.Clinical pulmonary medicine · 2016Article
- Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation.PloS one · 2016Article
- Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015Article
- Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.BMC infectious diseases · 2015Article
- A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation.The ISME journal · 2015Article
- Article
- Vaccination against respiratory Pseudomonas aeruginosa infection.Human vaccines & immunotherapeutics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic Fibrosis (CF) patients are vulnerable to airway colonization with Pseudomonas aeruginosa. In case eradication fails after antibiotic treatment, patients become chronically colonized with P. aeruginosa, with recurrent pulmonary exacerbation, for which patients typically are hospitalized for 2 weeks and receive intravenous antibiotic treatment. Normally, improvement of the patients' health is established.
aimDetermination of the correspondence between patient improvement and changes of the P. aeruginosa and total bacterial load in the sputum.
methodsEighteen CF patients with exacerbation were included for a total of 27 hospitalization episodes. At day 1, 8 and 15, inflammation and lung function parameters were determined, together with the P. aeruginosa load in the sputum using culture, quantitative PCR (qPCR) and propidium monoazide qPCR.
resultsPatients improved during hospitalization (decrease in levels of C-reactive protein, white blood cell counts and erythrocyte sedimentation rate, increase of FEV1), reaching normal values already after one week. Also the P. aeruginosa load and the total bacterial load decreased during the first week of antibiotic treatment (p<0.05), except for patients with a low lung function (FEV1≤39.4%), for whom no significant decrease of P. aeruginosa was established. Comparison of culture-based and propidium monoazide qPCR-based quantification of P. aeruginosa showed that at the end of the treatment on average 62% of the P. aeruginosa cells are not cultivable, indicating that many cells are alive but dormant, or dead but still structurally intact.
conclusionImprovement of the clinical status is accompanied with a decrease of the P. aeruginosa load, whereby both occur mainly during the first week of antibiotic treatment. However, for patients with a low lung function, no decrease of the P. aeruginosa load is observed. Comparison of detection techniques shows that a large amount of noncultivable or dead bacteria are present in the samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.